Revelation Biosciences In... (REVB)
0.48
-0.02 (-3.98%)
At close: Jan 14, 2025, 3:59 PM
0.46
-4.22%
Pre-market Jan 15, 2025, 08:35 AM EST
undefined% (undefined)
| Bid | 0.45 |
| Market Cap | 4.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -17.53 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.47 |
| Volume | 366,967 |
| Avg. Volume (20D) | 3,181,357 |
| Open | 0.49 |
| Previous Close | 0.50 |
| Day's Range | 0.45 - 0.53 |
| 52-Week Range | 0.28 - 25.26 |
| Beta | undefined |
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is a...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2020
Employees 9
Stock Exchange NASDAQ
Ticker Symbol REVB
Website https://www.revbiosciences.com
1 month ago ·
Source
+24.99%
Revelation Biosciences shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago ·
Source
-3.53%
Revelation Biosciences shares are trading higher after the company reported better-than-expected Q3 EPS results.
1 month ago · businesswire.com
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini INDSAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
